Quarterly report pursuant to Section 13 or 15(d)

RESTATEMENT

v3.19.2
RESTATEMENT
6 Months Ended
Sep. 30, 2018
Restatement [Abstract]  
RESTATEMENT
NOTE 2: RESTATEMENT
Restatement of Previously Issued Financial Statements
In February 2018, the Audit Committee (“Audit Committee”) of our Board of Directors (the “Board”), and subsequently a special committee of the Board (the “Special Committee”) consisting of two members of the Audit Committee, began conducting an internal investigation, with the assistance of independent accounting and legal advisors, into matters related to the Company’s accounting practices and internal control over financial reporting related to revenue recognition for transactions occurring between January 1, 2016 and March 31, 2018. Upon the recommendation of the Audit Committee and as a result of the investigation by the Special Committee and after consultation with the Company’s management, on September 14, 2018, the Company’s Board of Directors concluded that the Company’s previously issued consolidated financial statements and other financial data for the fiscal years ended March 31, 2017, 2016 and 2015 contained in the Company’s Annual Reports on Form
10-K
for the fiscal year ended March 31, 2017, and the Company’s condensed consolidated financial statements for each of the quarterly and
year-to-date
periods ended June 30, 2015, September 30, 2015, December 31, 2015, June 30, 2016, September 30, 2016, December 31, 2016, June 30, 2017 and September 30, 2017 (collectively, the
“Non-Reliance
Periods”) should not be relied upon and required restatement (the “Restatement”). The Board also determined that the Company’s disclosures related to these financial statements and related communications issued by or on behalf of the Company with respect to the
Non-Reliance
Periods, including management’s assessment of internal control over financial reporting and disclosure controls and procedures, should not be relied upon.
This Note discloses the nature of the Restatement adjustments and shows the impact of the restatement on revenues, expenses, income, assets, liabilities, equity, and cash flows from operating activities, investing activities and financing activities, and the cumulative effects of these adjustments on the consolidated balance sheets, statements of operations and comprehensive loss, statement of stockholders’ deficit and statements of cash flows for the six months ended September 30, 2017.
Restatement Background
On January 11, 2018, the Company received a subpoena from the Securities and Exchange Commission (“SEC”) seeking documents pertaining to the Company’s accounting practices and internal controls related to revenue recognition for transactions commencing April 1, 2016. The Company subsequently decided to postpone the release of Quantum’s results for the third quarter of fiscal 2018 and the Audit Committee began an independent investigation into the Company’s accounting practices and internal controls over financial reporting related to revenue recognition for transactions occurring between January 1, 2016 and March 31, 2018, with the assistance of independent accounting and legal advisors. Subsequently, the Special Committee, undertook to continue the investigation.
In September 2018, the Special Committee substantially completed and finalized its principal findings with respect to its investigation. The principal findings included a determination that the Company engaged in certain business and sales practices that may have undermined its historical accounting treatment for transactions with several key distributors and at least one end customer. The Special Committee found that the identified transactions potentially affected by such practices commenced at least in the fourth quarter of fiscal 2015 and continued at least through the fourth quarter of fiscal 2018 (the “Investigation Related Revenue Misstatements”). The Special Committee also found that these business and sales practices may have resulted in the Company recognizing revenue for certain transactions prior to satisfying the criteria for revenue recognition required under generally accepted accounting principles in the United States of America (“U.S. GAAP”).
In response to the findings of the Special Committee, the Company conducted a thorough review of its financial records for the fiscal years ended March 31, 2015, 2016 and 2017, and for each of the quarterly and year to date periods ended June 30, 2017 and September 30, 2017 to determine whether further adjustments were necessary. The Company concluded that there were material misstatements in the consolidated financial statements for the fiscal years ended March 31, 2015, 2016 and 2017 as well as the unaudited interim consolidated financial statements for the quarterly periods ended June 30, 2016, December 31, 2016, June 30, 2017 and September 30, 2017.
 
 
The Special Committee investigation is now complete, although our outside legal counsel, together with the assistance of the independent legal counsel to the Special Committee and independent accounting advisors, continue to provide support as requested in connection with the SEC investigation discussed in more detail in
Item 3—Legal Proceedings
contained in the Annual Report for fiscal 2019 on Form
10-K.
Description of Restatement Matters and Restatement Adjustments
The categories of restatement adjustments and their impact on previously reported consolidated financial statements are described below.
 
  (a)
Investigation Related Revenue –
As disclosed in Note 2:
Restatement
, the Company prematurely recognized product revenue sold to certain distributors, resellers and
end-user
customers. The associated product cost of revenue for each product revenue sales order was also recognized in the incorrect period. Additionally, for all transactions where product revenue was recognized prematurely, a reclassification is recorded at
sell-in
to reflect the movement of inventory at Quantum’s warehouse to inventory at its distributor’s warehouse. For the transactions where revenue was recognized prematurely, the Company restated the consolidated financial statements to reflect the revenue in the period in which the criteria for revenue recognition under U.S. GAAP have been satisfied. For revenue transactions where the criteria for revenue recognition under U.S. GAAP have not yet been satisfied, we deferred revenue recognition until all criteria are satisfied.
 
  (b)
Service Revenue Amortization Convention –
The Company inappropriately recognized service revenue on a monthly convention at the beginning of the initial month of service regardless of the service period start date resulting in an acceleration of revenue recognition. Additionally, certain annual service contracts were inappropriately recognized over a
13-month
period resulting in a deceleration of revenue recognition.
 
  (c)
Cash Consideration Paid to Customers –
The Company inappropriately recorded cash consideration paid to customers as expenses rather than as a reduction of revenue as such payments did not meet the identifiable benefit criteria within the Accounting Standards Codification (“ASC”) 605,
Revenue Recognition
(“Topic 605”) guidance. We have reclassified these expenses from sales and marketing expense to product revenue.
 
  (d)
Accrued Warranty –
The Company reviewed its warranty accrual methodology and determined that previous estimates did not appropriately reflect the Company’s historical experience. The Company changed its method in calculating the warranty accrual and applied the adjustments retroactively.
 
  (e)
Commissions Accrual –
Relating to misstatement (a), when the Company prematurely recognized revenue, the associated commission expense was also prematurely recognized. The Company restated commission expense to match the timing of associated revenue recognition.
 
  (f)
Short Term Disability Plan –
The Company inappropriately accounted for its employee funded disability plan and did not reflect employee contributions within restricted cash and did not recognize the obligation to fund disability claims as incurred.
 
  (g)
Third Party Maintenance Contracts
– The Company changed its method to appropriately account for capitalized third party maintenance contracts.
 
  (h)
Debt Issuance Costs –
The Company reclassified capitalized debt issuance costs on its revolver loan from long-term debt to a current asset.
 
  (i)
Restructuring –
The Company did not properly calculate expenses related to its restructuring activities, including failure to apply appropriate discount rates and omitting certain facilities in calculating the restructuring liabilities.
 
  (j)
Performance Based Stock Units –
The Company previously accrued stock-based compensation expense on performance-based stock units (“PSUs”) assuming the shares would be earned. The Company determined the likelihood of meeting the requirement conditions at the time was remote and therefore should not have recognized stock-based compensation expense for the related PSUs.
 
  (k)
Debt –
The Company incorrectly accounted for multiple amendments to the term loan and revolving credit agreements
resulting in errors in the treatment of debt extinguishment and issuance costs.
 
  (l)
General Presentation
– Certain activities in the statement of cash flows and consolidated balance sheets have been reclassified to conform with current fiscal year’s presentation.
  (m)
Australian Deferred Tax Assets and Valuation Allowance
– The Company failed to record deferred tax assets for certain
book-tax
differences at an Australian affiliate and to further establish a valuation allowance against certain of the tax assets.
 
  (n)
Deferred Tax Liability Related to Unrealized Swiss Currency Gains
– The Company misclassified and under accrued Swiss income tax on unrealized currency gains attributable to a dollar-denominated intercompany note receivable.
 
  (o)
Reserves for Uncertain Tax Positions on Transfer Pricing
– The Company did not accrue a reserve for foreign taxes payable due to uncertain tax positions relating to its transfer pricing for services and interest income on intercompany notes and payables.
 
  (p)
Valuation Allowance for State Credit Carryforward
– The Company failed to analyze all evidence, both positive and negative, when considering the future realization of its Texas state credit carryforward and inappropriately established a
100
% valuation allowance against the related deferred tax asset. The Company reevaluated the evidence and partially removed this valuation allowance.
 
  (q)
Tax Accounting
– The Company recalculated its income tax expense on an annual and quarterly basis to account for certain errors in the previous calculations of its federal income tax receivable, federal long-term income tax payable, and state income tax payable. Restatements impacting book income and various asset and liability accounts had no net effect on deferred taxes or tax expense due to the Company’s position of losses and a full valuation allowance.
 
  (r)
Other Adjustments
– There are other restatement matters otherwise not described in items (a) through (s) of this Note. The related adjustments are individually insignificant in the fiscal year ended March 31, 2017 but in aggregate are material to the consolidated financial statements. These misstatements include:
 
   
Unrecognized gain (loss) of cumulative translation adjustments upon the liquidation of certain foreign entities
 
   
Unrecognized asset retirement obligations
 
   
Incorrect accounting for a cost method investment
 
   
Accruals recorded in the incorrect accounting period
Consolidated financial statement adjustments tables
The following tables present the restatement adjustments to previously issued consolidated financial statements, including the previously reported consolidated balance sheet as of September 30, 2017, and the consolidated statement of operations and comprehensive loss, stockholders’ deficit and statement of cash flows for the six months ended September 30, 2017. The correction of misstatements affecting fiscal years prior to the six months ended September 30, 2017 are reflected as a cumulative adjustment to the April 1, 2017 stockholders’ deficit on the consolidated balance sheet and consolidated statement of stockholders’ deficit.
 
 
QUANTUM CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands)
 
   
September 30, 2017
 
   
As Reported
   
Restatement
Adjustments
   
Restatement
Reference
   
As Restated
 
ASSETS
                               
Current Assets
                               
Cash and cash equivalents
  $ 9,504     $ 4,479       k     $ 13,983  
Accounts receivable,
    105,771       (6,545     a       99,226  
Manufacturing inventories
    29,119       5,593       a       34,712  
Service part inventories
    19,915       —                 19,915  
Other current assets
    8,795       786       g, q       9,581  
Restricted cash
    1,969       1,094       f       3,063  
   
 
 
   
 
 
           
 
 
 
Total current assets
    175,073       5,407               180,480  
Property and equipment, less accumulated depreciation
    10,745       (325     r       10,420  
Restricted cash, long-term
    20,000       —                 20,000  
Other long-term assets
    5,332       1,418       h, m, p, r       6,750  
   
 
 
   
 
 
           
 
 
 
Total assets
  $ 211,150     $ 6,500             $ 217,650  
   
 
 
   
 
 
           
 
 
 
LIABILITIES AND STOCKHOLDERS’ DEFICIT
                               
Liabilities
                               
Current liabilities:
                               
Accounts payable
  $ 48,488       —               $ 48,488  
Accrued warranty
    2,950       (2,950     l       —    
Deferred revenue, current
    77,090       11,415       a, b       88,505  
Accrued restructuring charges, current
    1,743       627       i       2,370  
Convertible subordinated debt, current
    57,034       —                 57,034  
Accrued compensation
    23,180       (925     e, f       22,255  
Other accrued liabilities
    12,927       3,634       a, d, l, n, q, r       16,561  
   
 
 
   
 
 
           
 
 
 
Total current liabilities
    223,412       11,801               235,213  
Deferred revenue, long-term
    35,906       868       b       36,774  
Accrued restructuring charges, long-term
    423       3,192       i       3,615  
Long-term debt, net of current portion
    70,631       5,860       h, m       76,491  
Other long-term liabilities
    5,112       5,924       n, p, q       11,036  
   
 
 
   
 
 
           
 
 
 
Total liabilities
    335,484       27,645               363,129  
Commitment and contingencies (Note 12)
                               
Stockholders’ deficit
                               
Preferred stock
     —                      —  
Common stock
    347       —                 347  
Additional
paid-in
capital
    476,409       (316     j       476,093  
Accumulated deficit
    (604,832     (16,197     a, b, d, e, m, o,
p, q, r
      (621,029
Accumulated other comprehensive income (loss)
    3,742       (4,632     n, r       (890
   
 
 
   
 
 
           
 
 
 
Total stockholders’ deficit
    (124,334     (21,145             (145,479
   
 
 
   
 
 
           
 
 
 
Total liabilities and stockholders’ deficit
  $ 211,150     $ 6,500             $ 217,650  
   
 
 
   
 
 
           
 
 
 
QUANTUM CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(in thousands, except per share amounts)
 
   
Six Months Ended September 30, 2017
 
   
As Reported
   
Restatement
Adjustments
   
Restatement
References
   
As Restated
 
Revenue:
                               
Product revenue
  $ 135,224     $ 1,855       a, c     $ 137,079  
Service revenue
    69,410       617       b       70,027  
Royalty revenue
    19,275       —                 19,275  
   
 
 
   
 
 
           
 
 
 
Total revenue
    223,909       2,472               226,381  
   
 
 
   
 
 
           
 
 
 
Costs and expenses:
                               
Product cost of revenue
    99,510       2,772       a       102,282  
Service cost of revenue
    29,807       135       d       29,942  
Total cost of revenue
    129,317       2,907               132,224  
   
 
 
   
 
 
           
 
 
 
Gross profit
    94,592       (435             94,157  
   
 
 
   
 
 
           
 
 
 
Operating expenses:
                               
Research and development
    20,795       —                 20,795  
Sales and marketing
    54,003       (1,101     c, e       52,902  
General and administrative
    24,667       (737     j, r       23,930  
Restructuring charges
    2,366       (665     i       1,701  
   
 
 
   
 
 
           
 
 
 
Total operating expenses
    101,831       (2,503             99,328  
   
 
 
   
 
 
           
 
 
 
Loss from operations
    (7,239     2,068               (5,171
Other expenses and losses, net:
                               
Interest expense, net
    5,175       42       r       5,217  
Loss on debt extinguishment
    39       —                 39  
Other income, net
    (175     —                 (175
   
 
 
   
 
 
           
 
 
 
Loss before income taxes
    (12,278     2,026               (10,252
Income tax benefit
    (741     (293     m, o, p, q       (1,034
   
 
 
   
 
 
           
 
 
 
Net loss
  $ (11,537   $ 2,319             $ (9,218
   
 
 
   
 
 
           
 
 
 
Net loss per share:
                               
Basic
  $ (0.34                   $ (0.27
Diluted
  $ (0.34                   $ (0.27
         
Weighted average common shares outstanding - basic
    34,337                       34,338  
Weighted average common shares outstanding - diluted
    34,337                       34,338  
 
 
   
Three Months Ended September 30, 2017
 
   
As Reported
   
Restatement
Adjustments
   
Restatement
References
   
As Restated
 
Revenue:
                               
Product revenue
  $ 63,606     $ 3,990       a, c     $ 67,596  
Service revenue
    34,165       745       b       34,910  
Royalty revenue
    9,280       —                 9,280  
   
 
 
   
 
 
           
 
 
 
Total revenue
    107,051       4,735               111,786  
   
 
 
   
 
 
           
 
 
 
Costs and expenses:
                               
Product cost of revenue
    48,561       3,041       a       51,602  
Service cost of revenue
    14,717       148       d       14,865  
Total cost of revenue
    63,278       3,189               66,467  
   
 
 
   
 
 
           
 
 
 
Gross profit
    43,773       1,546               45,319  
   
 
 
   
 
 
           
 
 
 
Operating expenses:
                               
Research and development
    10,190       —                 10,190  
Sales and marketing
    26,179       (355     c, e       25,824  
General and administrative
    12,158       (652     j, r       11,506  
Restructuring charges
    31       39       i       70  
   
 
 
   
 
 
           
 
 
 
Total operating expenses
    48,558       (968             47,590  
   
 
 
   
 
 
           
 
 
 
Loss from operations
    (4,785     2,514               (2,271
Other expenses and losses, net:
                               
Interest expense, net
    2,617       21       r       2,638  
Loss on debt extinguishment
    39       —                 39  
Other income, net
    (77     —                 (77
   
 
 
   
 
 
           
 
 
 
Loss before income taxes
    (7,364     2,493               (4,871
Income tax expense
    499       (271     m, o, p, q       228  
   
 
 
   
 
 
           
 
 
 
Net loss
  $ (7,863   $ 2,764             $ (5,099
   
 
 
   
 
 
           
 
 
 
Net loss per share:
                               
Basic
  $ (0.23                   $ (0.15
Diluted
  $ (0.23                   $ (0.15
         
Weighted average common shares outstanding - basic
    34,561                       34,580  
Weighted average common shares outstanding - diluted
    34,561                       34,580  
 
 
QUANTUM CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
 
   
For the Six Months Ended September 30, 2017
 
   
As Reported
   
Restatement
Adjustments
   
Restatement
Reference
   
As Restated
 
Cash flows from operating activities:
                               
Net loss
  $ (11,537   $ 2,319       a, b, e, f, g,
h, i, l, n, p, q
    $ (9,218
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
                               
Depreciation and amortization
    2,525       85       l, r       2,610  
Amortization of debt issuance costs
    855       —                 855  
Product and service parts lower of cost or market adjustment
    2,319       1,844       l       4,163  
Tax benefit from settlement
    (1,656     1,656       l       —    
Share-based compensation expense
    3,330       (317     l       3,013  
Non-cash
interest expense
    621       (621     l       —    
Non-cash
loss on debt extinguishment
    9       30       l       39  
Pension expense
    —         733       l       733  
Bad debt expense
    —         292       l       292  
Deferred income taxes, net
    144       (463     l, m, o, p       (319
Loss on disposal of property and equipment
    —         2       l       2  
Unrealized foreign exchange (gain)/loss
    —         1,019       l       1,019  
Loss on investments
    —         72       l       72  
Changes in assets and liabilities:
                               
Accounts receivable
    10,284       (7,219     a, l       3,065  
Manufacturing inventories
    (1,752     553       a, l       (1,199
Service parts inventories
    (2,737     353       l       (2,384
Accounts payable
    6,537       838       g, l       7,375  
Accrued warranty
    (313     313       l       —    
Accrued restructuring charges
    817       (1,114     e, f, g       (297
Accrued compensation
    (1,236     (1,031     i, l       (2,267
Deferred revenue
    (9,329     3,382       a, b, l       (5,947
Other assets and liabilities
    815       (3,728 )     a, d, g, h, l,
m, n, p, q
      (2,913
   
 
 
   
 
 
           
 
 
 
Net cash used in operating activities
    (304     (1,002             (1,306
   
 
 
   
 
 
           
 
 
 
Cash flows from investing activities:
                               
Purchases of property and equipment
    (1,156     5       l       (1,151
Proceeds from sale of assets
    —         275       l       275  
Cash distributions from investments
    278       —                 278  
   
 
 
   
 
 
           
 
 
 
Net cash used in investing activities
    (878     280               (598
   
 
 
   
 
 
           
 
 
 
Cash flows from financing activities:
                               
Borrowings of long-term debt and subordinated convertible debt, net of debt issuance costs
    164,650       620       k       165,270  
Repayments on long-term debt
    (160,245     4,479       k       (155,766
Repayment of convertible subordinated debt
    (6,000     (30     l       (6,030
Payment of tax withholding due upon vesting of restricted stock
    (1,775     (2     l       (1,777
Proceeds from issuance of common stock, net
    1,010       2       l       1,012  
   
 
 
   
 
 
           
 
 
 
Net cash provided by (used in) financing activities
    (2,360     5,069               2,709  
   
 
 
   
 
 
           
 
 
 
Effect of exchange rate changes on cash, cash equivalents and restricted cash
    82       247       l       329  
   
 
 
   
 
 
           
 
 
 
Net decrease in cash, cash equivalents and restricted cash
    (3,454     4,588               1,134  
Cash, cash equivalents and restricted cash at the beginning of period
    36,658       (746             35,912  
   
 
 
   
 
 
           
 
 
 
Cash, cash equivalents and restricted cash at the end of period
  $ 33,204     $ 3,842             $ 37,046  
   
 
 
   
 
 
           
 
 
 
Supplemental disclosure of cash flow information:
                               
Purchases of property and equipment included in accounts payable
  $ 335     $ (48     l     $ 287  
Transfer of inventory to property and equipment
  $ —       $ 919       l     $ 919  
Cash Paid For:
                               
Interest
  $ —       $ 4,515       l     $ 4,515  
Taxes, net of refunds
  $ —       $ 914       l     $ 914